2.7-Dimethyl-4-octen-3.6-dion | 62738-21-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2.7-Dimethyl-4-octen-3.6-dion
• 英文别名: 2,7-Dimethyl-4-octene-3,6-dione；(E)-2,7-dimethyloct-4-ene-3,6-dione
• CAS: 62738-21-0
• 化学式: C₁₀H₁₆O₂
• 分子量: 168.236
• InChiKey: AQPCVFUWAFVTHX-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2.7-Dimethyl-4-octen-3.6-dion 、 溴 以75%的产率得到
  参考文献：
  名称：

  LUHMANN U.; WENTZ F. G.; LUETTKE W.; SUESSE P., CHEM. BER. , 1977, 110, NO 4, 1421-1431

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲基-1-戊烯-3-酮 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 2-methylhept-1-en-4-yl acetate 作用下， 以 二氯甲烷 为溶剂， 生成 2.7-Dimethyl-4-octen-3.6-dion
  参考文献：
  名称：

  Highly Demanding Cross-Metathesis in the Synthesis of the C16–C30 Fragment of Dolabelide C

  摘要：

  A highly demanding cross-metathesis (CM) reaction for the formation of the C24-C25 trisubstituted olefin of dolabelide C has been optimized. A difference in reactivity between the E and Z enone isomers in this reaction was uncovered, and the selection of the Z isomer of the starting enone was critical for the success of the cross-metathesis. Application to the synthesis of the C16-C30 fragment of dolabelide C is reported.

  DOI：

  10.1021/jo200466t

文献信息

• [EN] TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS DE DÉRIVÉS DE TRÉPROSTINIL ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CORSAIR PHARMA INC

  公开号：WO2016010538A1

  公开（公告）日：2016-01-21

  Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

  由I、II、III和IV式代表的化合物包括曲前列素和前列环素类似物的前药。用途包括治疗肺动脉高压（PH）或肺动脉高压（PAH）。这些化合物的结构可以根据适当的治疗剂量调整以适应特定的应用。可以使用经皮应用。
• [EN] PRODRUGS OF TREPROSTINIL<br/>[FR] PROMÉDICAMENTS DE TRÉPROSTINIL
  申请人：THERATROPHIX LLC

  公开号：WO2014110491A1

  公开（公告）日：2014-07-17

  Prodrugs of treprostinil are provided which can be used in the treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

  Treprostinil的前药提供了，可用于治疗肺动脉高压（PH）或肺动脉高压（PAH）。这些化合物的结构可以根据适当的治疗剂量适应特定应用。可以使用经皮应用。
• PRODRUGS OF GUANFACINE
  申请人：Whomsley Rhys

  公开号：US20110065796A1

  公开（公告）日：2011-03-17

  Prodrugs of guanfacine with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration, as well as improving the pharmacokinetics of guanfacine are provided herein.

  本文提供了具有氨基酸或短肽的瓜那非辛前药、含有这种前药的药物组合物以及一种利用瓜那非辛前药在治疗注意力缺陷多动障碍/反抗性违抗障碍（ADHD/ODD）中提供治疗益处的方法。此外，本文还提供了减少或避免与瓜那非辛给药相关的不良胃肠道副作用的方法，以及改善瓜那非辛的药代动力学的方法。
• USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS
  申请人：Franklin Richard

  公开号：US20120202756A1

  公开（公告）日：2012-08-09

  The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics.

  本发明涉及各种药物的前药和含有这些前药的制药组合物。还提供了一种方法，用于最小化与未衍生药物相关的局部介导（来自肠腔内）不良胃肠事件，并使用上述前药增加血浆药物水平的持续性。因此，本发明涉及使用各种药物（除阿片类药物外）的前药，以短暂地使它们失活，从而减少通常在给予原始化合物后出现的直接、局部介导的不良胃肠（GI）副作用。此外，这些前药可能提供改善的药代动力学。
• TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME
  申请人：Corsair Pharma, Inc.

  公开号：US20150166503A1

  公开（公告）日：2015-06-18

  Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

  式子 I、II、III 和 IV 所代表的化合物包括替前列环素和前列环素类似物的前药。用途包括治疗肺高压（PH）或肺动脉高压（PAH）。这些化合物的结构可以根据适当的治疗剂量适应特定的应用。可以使用经皮应用。